Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
IMNM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.15 - $16.55
Previous CloseN/A
Volume79.27K
Average Volume (3M)912.30K
Market Cap
$825.19M
Enterprise Value$545.31M
Total Cash (Recent Filing)$268.04M
Total Debt (Recent Filing)$4.14M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 17, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding87,045,006
10 Day Avg. Volume1,444,108
30 Day Avg. Volume912,301
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue43.32
Enterprise Value/Gross Profit43.32
Enterprise Value/Ebitda-2.90
Forecast
1Y Price Target
$23.67Price Target Upside160.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessConfidence in a positive outcome for varegacestat in Phase 3 desmoid tumor data is supported by KOL feedback.
Competitive AdvantageVaregacestat's QD dosing schedule is noted as a key advantage that will drive preferential uptake compared to nirogacestat's BID schedule.
Financial StabilityCash and cash equivalents are $268 million, which provides a runway into 2027.
Bears Say
Clinical Data ConcernsSkeptics question the reliability of smaller N, single-arm Phase 2 data and whether better efficacy can come without greater on-target toxicities.
Market SentimentShort interest is at 20.1% of the float.
Potential Efficacy ConcernsThere is a risk that varegacestat may show worse-than-expected efficacy or an unexpected safety signal in Phase 3.
Immunome News
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $5.15 and its highest was $16.55 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $825.19M.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Nov 17, 2025 which is in 60 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Aug 06, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.517 by $0.017.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.57.
How many shares outstanding does Immunome have?
Immunome has 87,045,006 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.517. Following the earnings report the stock price went down -5.641%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.67 (160.40% Upside)
$23.67 (160.40% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 786.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.63%
12-Months-Change
Fundamentals
Return on Equity
-81.20%
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Immunome
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
IMNM Stock 12 Month Forecast
Average Price Target
$23.67
▲(160.40% Upside)
Technical Analysis
Prothena
―
KalVista Pharmaceuticals
―
Dianthus Therapeutics
―
Trevi Therapeutics
―
Pharming Group
―
Ownership Overview
1.59% Insiders
23.70% Mutual Funds
46.65% Other Institutional Investors
17.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---